Operating Lease, Payments of ARROWHEAD PHARMACEUTICALS, INC. from 30 Sep 2018 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
ARROWHEAD PHARMACEUTICALS, INC. quarterly and annual Operating Lease, Payments in USD history and change rate from 30 Sep 2018 to 31 Dec 2025.
  • ARROWHEAD PHARMACEUTICALS, INC. Operating Lease, Payments for the quarter ending 31 Dec 2025 was $3,943,000, a 2.7% increase year-over-year.
  • ARROWHEAD PHARMACEUTICALS, INC. Operating Lease, Payments for the twelve months ending 31 Dec 2025 was $15,577,000, a 22% increase year-over-year.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Operating Lease, Payments for 2025 was $15,474,000, a 40% increase from 2024.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Operating Lease, Payments for 2024 was $11,038,000, a 112% increase from 2023.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Operating Lease, Payments for 2023 was $5,204,000, a 16% increase from 2022.
Source SEC data
View on sec.gov
Operating Lease, Payments, Trailing 12 Months (USD)
Operating Lease, Payments, Quarterly (USD)
Operating Lease, Payments, YoY Quarterly Change (%)
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Change (%)

ARROWHEAD PHARMACEUTICALS, INC. Quarterly Operating Lease, Payments (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $15,577,000 $3,943,000 +$103,000 +2.7% 01 Oct 2025 31 Dec 2025 10-Q 05 Feb 2026 2026 Q1
Q3 2025 $15,474,000 $3,919,000 +$211,000 +5.7% 01 Jul 2025 30 Sep 2025 10-K 25 Nov 2025 2025 FY
Q2 2025 $15,263,000 $3,875,000 +$671,000 +21% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q3
Q1 2025 $14,592,000 $3,840,000 +$1,794,000 +88% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q2
Q4 2024 $12,798,000 $3,840,000 +$1,760,000 +85% 01 Oct 2024 31 Dec 2024 10-Q 05 Feb 2026 2026 Q1
Q3 2024 $11,038,000 $3,708,000 +$2,818,000 +317% 01 Jul 2024 30 Sep 2024 10-K 25 Nov 2025 2025 FY
Q2 2024 $8,220,000 $3,204,000 +$1,319,000 +70% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q3
Q1 2024 $6,901,000 $2,046,000 +$948,000 +86% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q2
Q4 2023 $5,953,000 $2,080,000 +$749,000 +56% 01 Oct 2023 31 Dec 2023 10-Q 10 Feb 2025 2025 Q1
Q3 2023 $5,204,000 $890,000 01 Jul 2023 30 Sep 2023 10-K 25 Nov 2025 2025 FY
Q2 2023 $1,885,000 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q3
Q1 2023 $1,098,000 -$1,073,000 -49% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q2
Q4 2022 $1,331,000 +$331,000 +33% 01 Oct 2022 31 Dec 2022 10-Q 06 Feb 2024 2024 Q1
Q1 2022 $2,171,000 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q2
Q4 2021 $1,000,000 +$300,000 +43% 01 Oct 2021 31 Dec 2021 10-Q 02 Feb 2022 2022 Q1
Q4 2020 $2,200,000 $700,000 +$400,000 +133% 01 Oct 2020 31 Dec 2020 10-Q 02 Feb 2022 2022 Q1
Q3 2020 $1,800,000 $700,000 01 Jul 2020 30 Sep 2020 10-K 22 Nov 2021 2021 FY
Q2 2020 $500,000 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2020 2020 Q3
Q1 2020 $300,000 01 Jan 2020 31 Mar 2020 10-Q 07 May 2020 2020 Q2
Q4 2019 $300,000 01 Oct 2019 31 Dec 2019 10-Q 04 Feb 2021 2021 Q1

ARROWHEAD PHARMACEUTICALS, INC. Annual Operating Lease, Payments (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $15,474,000 +$4,436,000 +40% 01 Oct 2024 30 Sep 2025 10-K 25 Nov 2025 2025 FY
2024 $11,038,000 +$5,834,000 +112% 01 Oct 2023 30 Sep 2024 10-K 25 Nov 2025 2025 FY
2023 $5,204,000 +$704,000 +16% 01 Oct 2022 30 Sep 2023 10-K 25 Nov 2025 2025 FY
2022 $4,500,000 +$1,400,000 +45% 01 Oct 2021 30 Sep 2022 10-K 26 Nov 2024 2024 FY
2021 $3,100,000 +$1,300,000 +72% 01 Oct 2020 30 Sep 2021 10-K 29 Nov 2023 2023 FY
2020 $1,800,000 +$500,000 +38% 01 Oct 2019 30 Sep 2020 10-K 22 Nov 2021 2021 FY
2019 $1,300,000 $0 0% 01 Oct 2018 30 Sep 2019 10-K 22 Nov 2021 2021 FY
2018 $1,300,000 01 Oct 2017 30 Sep 2018 10-K 23 Nov 2020 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.